Evidence map›Paper›PMID 41369964›Full record

ReviewMolecular biology reports2025

Ketamine enantiomers and the gut microbiota: mechanisms, clinical implications, and future directions.

Jin-Xi Xie, Li-Wen Zhou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jin-Xi XieHubei University of Arts and Science, Xiangyang, 441100, China.
Li-Wen ZhouDepartment of Anesthesiology, Xiangyang Central Hospital, Affiliated to Hubei University of Arts and Science, No.136 Jingzhou Street, Xiangyang, 441100, China. zhoulw123@sina.com.

Funding

Chen Xiao-Ping Foundation for The Development of Science and Technology of Hubei Province CXPJJH12000005-07-37
6 · The paper itself

Abstract

There is a complex, bidirectional interaction between the gut microbiota and the central nervous system, known as the gut-brain axis. Esketamine, as the right-handed isomer of ketamine, has been approved by the US FDA for the treatment of treatment-resistant depression (TRD), and its rapid antidepressant effect may involve modulation of gut microbiota. In addition, other ketamine isomers (such as R-ketamine) and racemic mixtures (R, S-ketamine) may also affect the gut microbiota through different pathways. This article reviews the potential regulatory mechanisms of ketamine and its isomers on gut microbiota, including anti-inflammatory effects, regulation of neurotransmitter metabolism, and intestinal barrier repair. It discusses, their clinical implications and future research directions.

Indexed as

Gastrointestinal MicrobiomeKetamineAnimalsAntidepressive AgentsAnti-Inflammatory AgentsHumansStereoisomerismAntidepressive AgentsAnti-Inflammatory AgentsEsketamineKetamineDepressionEsketamineGut brain axisGut microbiota

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.